The latest update is out from PainReform ( (PRFX) ).
On January 2, 2025, PainReform Ltd. announced an increase in the aggregate offering price of its ordinary shares to up to $4.0 million under an At-the-Market Offering Agreement with H.C. Wainwright & Co., LLC. This move, facilitated through a prospectus supplement filed with the SEC, aims to bolster the company’s financial resources, potentially impacting its market positioning and providing additional capital for its operations.
More about PainReform
PainReform Ltd. operates in the pharmaceutical industry, focusing on the development and commercialization of reformulated pain therapeutics. The company is based in Tel Aviv, Israel, and is engaged in enhancing the efficacy and safety of existing pain medications.
YTD Price Performance: -7.72%
Average Trading Volume: 3,613,417
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.62M
See more data about PRFX stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com